WELCOME TO The Biotechnology REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Diverse Biotech | May 04, 2020
Diverse Biotech, Inc. www.diversebiotech.com has announced the U.S. Food & Drug Administration (FDA) has granted an orphan-drug designation request for one of its investigational new therapies for treatment of newly diagnosed glioblastoma, in conjunction with standard treatment, following adjuvant combined chemo-radiation. Orphan designation qualifies the sponsor of the drug for various development incentives of the ODA, (Orphan Drug Act) including tax credits for qualified clinical te...
Investors Chronicle | April 30, 2020
Healthcare companies around the world are scrambling to produce drugs and vaccines to treat and immunise people against Covid-19. However, the managers of International Biotechnology Trust (IBT) are not necessarily investing in these companies as their share prices are volatile, shooting up on reports of possible treatments in development.For example, Carl Harald Janson, lead manager of International Biotechnology Trust, recently reduced the trust’s holding in Gilead Sciences (US:GIL...
Horizon | October 03, 2022
Horizon Therapeutics plc announced the presentation of new data defining molecular patterns in TED and further implicating the role of insulin-like growth factor-1 in patients with low CAS. These data were presented during the American Academy of Ophthalmology Annual Meeting Sept. 30 – Oct. 3 in Chicago.
TED is a progressive and potentially vision-threatening rare autoimmune disease, which has been historically characterized as biphasic: acute, which is traditionally believe...
CELL AND GENE THERAPY
ginkgo biowork | November 11, 2021
ginkgo biowork the leading horizontal platform for cell programming, announced the launch of its Cell Development Kits (CDKs) service. CDKs provide streamlined access to the company's platform for aspiring cell developers to program cells to tackle the biggest challenges facing society. The first CDKs to launch are focused on protein expression programs. The service provides developers access to the toolkit needed to get started developing commercial proteins, including pre-engineered ...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE